American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
Guardant Health’s FDA-approved Shield blood test has been included in the updated American Cancer Society (ACS) Colorectal Cancer Screening Guidelines. The guidelines recommend Shield as a new option for the more than 50 million eligible Americans who are not up to date with screening, particularly those who decline stool-based or visual exams.
Key figures
- Drug Name
- Shield
- Eligible population
- 50 million
- Sensitivity stage 2 plus
- 100%
- Screening completion rate
- 90%
- Patients tested real world
- 200,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.